First, it offers a rationale for the combinatorial use of BTK inhibitors and ferroptosis inducers in patients with relapsed or refractory DLBCL, particularly those with NF-κB–addicted ABC subtypes. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.